Cencora to Acquire EyeSouth Partners’ Retina Business for \$1.1 Billion

Key Points from the Report

• Acquisition Announcement: Cencora, Inc. (NYSE: COR) has entered into a definitive agreement to acquire EyeSouth Partners’ retina business for \$1.1 billion.
• Integration: Following the transaction, EyeSouth Partners’ affiliated retina physicians will join Cencora’s Retina Consultants of America (RCA), a leading management services organization (MSO) focused on retina care.
• Strategic Rationale: The acquisition is intended to strengthen Cencora’s position in the retina care market, expand RCA’s network, and enhance capabilities in sight-saving treatments and clinical research.
• Financial Impact: The acquisition is expected to be slightly accretive to adjusted diluted earnings per share (EPS), net of financing costs, within the first twelve months post-closing.
• Guidance: Cencora reaffirmed its fiscal 2026 financial guidance, which does not currently assume the transaction will close during fiscal 2026.
• Closing Conditions: The transaction is subject to customary closing conditions, including regulatory approvals.
• Advisors: BofA Securities and Citi are financial advisors to Cencora; Sidley Austin LLP, legal advisor. Jefferies LLC and Kirkland & Ellis LLP represent EyeSouth Partners, a portfolio company of Olympus Partners.

Details Investors Should Note

• Strategic Expansion: EyeSouth Partners has a strong regional network of retina physicians. By joining RCA, these physicians gain access to RCA’s resources, research programs, and Cencora’s broader pharmaceutical expertise.
• Leadership Commentary: Cencora’s CEO, Robert P. Mauch, emphasized the acquisition’s alignment with its commitment to empowering ophthalmologists and supporting community physicians. RCA’s Chief Medical Officer, Dr. David Brown, highlighted the opportunity to advance sight-saving treatments. Dr. Atul Sharma of EyeSouth Partners added that joining RCA will expand access to innovative treatments and enhance research efforts.
• Financial Sensitivity: The deal’s accretive impact on EPS and the reaffirmation of financial guidance could influence investor sentiment and share valuation. However, uncertainty remains regarding the exact timing of closing.
• Risk Factors: The deal faces standard risks such as regulatory approvals, integration challenges, potential for business disruption, retention of key staff, and customer/supplier relationship changes. Cencora’s ability to maintain its investment-grade rating and execute de-leveraging plans are also highlighted as considerations for shareholders.
• Company Profile: Cencora is a major global pharmaceutical solutions provider, ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with over \$300 billion in annual revenue and more than 51,000 employees worldwide.
• Forward-Looking Statements: The press release contains forward-looking statements subject to risks and uncertainties, including the possibility that expected benefits and synergies may not be realized, or that the transaction may not close as anticipated.

Potential Share Price Sensitivity

This acquisition is significant and likely to be price sensitive for Cencora’s shares. The \$1.1 billion deal expands Cencora’s specialty healthcare footprint and positions the company to capture further growth in the high-value retina care segment. Investors should monitor regulatory developments, closing progress, and any updates to Cencora’s financial guidance. The transaction’s accretive nature, if realized, could support future share price appreciation, though integration and regulatory risks must be considered.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review all available information and consult their financial advisor before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those discussed.

View Cencora, Inc. Historical chart here